“…Several circulating markers, such as uric acid, alanine aminotransferase, adiponectin, leptin, resistin, retinol binding protein 4, plasminogen activator inhibitor-1 and other inflammatory markers, as well as novel adiposity markers, such as epicardial fat, have been associated with MS, fueling the research on the pathogenesis, long-term prediction and treatment of cardio-metabolic disease [17,76,77,78,79,80]. However, their clinical advantages as markers of MS have not been assessed, so that their use as screening tools for MS is not justified [17,76,77,78,79,80].…”